SPEAKER
(S):
Transfusion-related iron overload (TRIO)/iron toxicity is a serious adverse outcome of red blood cell transfusions for those patients receiving approximately 20 units of RBCs or more over their lifetime for non-bleeding diagnoses. Patients transfused with 20 or more RBCs for treatment of myelodysplastic syndrome (MDS), sickle cell disease (SCD), Diamond-Blackfan anemia (DBA), ∝-thalassemia, or bone marrow transplant (BMT) should be monitored for TRIO and for when chelation treatment may be indicated. This presentation will discuss monitoring, diagnosis, and treatment of transfusion-related iron overload/iron toxicity.
This session offers Self-Assessment Module (SAM) credit. Please complete the post test to receive SAM credit.